Quoin Pharmaceuticals Ltd... (QNRX)
Quoin Pharmaceuticals Statistics
Share Statistics
Quoin Pharmaceuticals has 255.66K shares outstanding. The number of shares has increased by 135.73% in one year.
| Shares Outstanding | 255.66K |
| Shares Change (YoY) | 135.73% |
| Shares Change (QoQ) | 77.2% |
| Owned by Institutions (%) | 0.03% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 3 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 12.51K, so 0.06% of the outstanding shares have been sold short.
| Short Interest | 12.51K |
| Short % of Shares Out | 0.06% |
| Short % of Float | 0.07% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
| PE Ratio | 0 |
| Forward PE | -16.74 |
| PS Ratio | 0 |
| Forward PS | 0 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Quoin Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.57, with a Debt / Equity ratio of 0.
| Current Ratio | 3.57 |
| Quick Ratio | 3.57 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-2,987,490,666.67 |
| Employee Count | 3 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 773.97% in the last 52 weeks. The beta is 1.61, so Quoin Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.61 |
| 52-Week Price Change | 773.97% |
| 50-Day Moving Average | 6.25 |
| 200-Day Moving Average | 2.01 |
| Relative Strength Index (RSI) | 49.82 |
| Average Volume (20 Days) | 233,553 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | n/a |
| Net Income | -8.96B |
| EBITDA | n/a |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1911.5 |
Balance Sheet
The company has 3.62B in cash and 0 in debt, giving a net cash position of 3.62B.
| Cash & Cash Equivalents | 3.62B |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -55.17B |
| Total Assets | 15.71B |
| Working Capital | 10.75B |
Cash Flow
In the last 12 months, operating cash flow was -7.86B and capital expenditures 0, giving a free cash flow of -7.86B.
| Operating Cash Flow | -7.86B |
| Capital Expenditures | n/a |
| Free Cash Flow | -7.86B |
| FCF Per Share | -1675.79 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
QNRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for QNRX is $4, which is -37.3% lower than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | -37.3% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jul 18, 2023. It was a backward split with a ratio of 1:12.
| Last Split Date | Jul 18, 2023 |
| Split Type | backward |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | -4.1 |
| Piotroski F-Score | 2 |